国际医药卫生导报2015，Vol.21Issue(16)：2417-2419,3.DOI:10.3760/cma.j.issn.1007-1245.2015.16.038
重组人白细胞介素-2辅助治疗复治肺结核的临床分析
Clinical analysis of adjuvant therapy with recombinant human interleukin-2 in the treatment of retreatment pulmonary tuberculosis
摘要
Abstract
Objective To explore clinical effect of adjuvant therapy with recombinant human interleukin-2 (rh IL-2) in the treatment of retreatment pulmonary tuberculosis.Methods 54 cases of retreatment pulmonary tuberculosis in our hospital from October 2014 to January 2015 were selected and randomly divided into control group and study group.27 cases in control group were given routine comprehensive treatment,while 27 cases in study group were added adjuvant therapy with rh IL-2 on the basis of control group.Sputum negative conversion,focal absorption and cavity closure of two groups were observed after the full course.Results (1) The bacteriological examination showed that the rate of sputum negative conversion of study group was 88.89％,significantly higher than 70.37％ of control group,with statistically significant difference (P＜0.05).(2)X-ray examination showed that focal absorption and cavity closure results were superior to those of control group,with statistically significant differences (P＜0.05).Conclusion Recombinant human interleukin-2 is used in the adjuvant therapy to treat pulmonary tuberculosis,which can significantly improve curative effect,and can be used as a reliable and safe treatment method.关键词
结核杆菌/肺结核/重组人白细胞介素-2Key words
Mycobacterium tuberculosis/Pulmonary tuberculosis/Recombinant human interleukin-2引用本文复制引用
梁瑞霞..重组人白细胞介素-2辅助治疗复治肺结核的临床分析[J].国际医药卫生导报,2015,21(16):2417-2419,3.
